Glucagon-Like Peptide 2

A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.

Also Known As:

Networked: 107 relevant articles (12 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Holst, Jens J: 7 articles (01/2019 - 11/2006)
2.	Sigalet, David L: 7 articles (05/2018 - 08/2009)
3.	Hartmann, Bolette: 5 articles (01/2019 - 07/2007)
4.	Jeppesen, Palle B: 5 articles (06/2014 - 07/2007)
5.	Jeppesen, P B: 5 articles (10/2013 - 09/2005)
6.	Holst, J J: 4 articles (06/2013 - 08/2004)
7.	Mortensen, P B: 4 articles (06/2013 - 09/2005)
8.	Stoll, Barbara: 3 articles (01/2020 - 06/2014)
9.	Thymann, Thomas: 3 articles (01/2020 - 06/2014)
10.	Boctor, Dana: 3 articles (05/2018 - 01/2017)

Related Diseases

1.	Short Bowel Syndrome 01/01/2017 - "We aim to study the efficacy of exogenously administered glucagon-like peptide 2 (GLP-2) on intestinal adaptation in 2 preclinical models of neonatal short bowel syndrome (SBS) according to remnant intestinal anatomy, with and without ileum. " 01/01/2009 - "In a short-term study, Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients. " 01/01/2009 - "Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study. " 01/01/2019 - "NEW & NOTEWORTHY Therapeutic activation of endogenous glucagon-like peptide 2 (GLP-2) secretion is a promising strategy to improve intestinal adaptation in patients with short bowel syndrome. " 01/01/2019 - "Enteroendocrine L cells and glucagon-like peptide 2 (GLP-2) secretion are activated in the intestinal adaptation process following bowel resection in patients with short bowel syndrome. "
2.	Enteritis 06/01/2000 - "Glucagon-like peptide 2: a new treatment for chemotherapy-induced enteritis." 11/01/1999 - "Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis."
3.	Inflammation (Inflammations) 06/01/2019 - "In this study, we evaluate the effects of glucagon-like peptide 2 (GLP-2) on bone microarchitecture, bone turnover markers (BTMs) and inflammation markers in ovariectomized (OVX) rats. " 11/01/2017 - "Objectives were to characterize how progressive feed restriction (FR) affects inflammation, metabolism, and intestinal morphology, and to investigate if glucagon-like peptide 2 (GLP2) administration influences the aforementioned responses. " 12/01/2010 - "Glucagon-like peptide 2 (GLP-2) reduces intestinal inflammation and has trophic effects on isolated neurons. " 12/01/2010 - "The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation." 12/01/2018 - "Glucagon-like peptide 2 (GLP-2) is a hormone that has been shown to stimulate intestinal growth and attenuate intestinal inflammation. "
4.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/01/2000 - "Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells." 01/01/2017 - "As an intestinal growth factor, glucagon-like peptide 2 (GLP-2) has been shown to improve the preclinical models of both short bowel syndrome and inflammatory bowel disease by stimulating intestinal growth. " 01/01/2012 - "Glucagon-like peptide 2 (GLP2) is an intestinal growth factor that has been shown to stimulate intestinal growth and reduce disease severity in preclinical models of short bowel syndrome and inflammatory bowel disease. " 12/01/2021 - ": UC, Ulcerative colitis; IBD, Inflammatory bowel disease; DEGs, Differentially expressed genes; GEO, Gene Expression Omnibus; SVA, Spatial variant apodization; LIMMA, Linear models for the microarray data; FC, Fold change; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSVA, Gene Set Variation Analysis; MSigDB, Molecular Signatures Database; WT, Wild-type; DSS, Dextran sulfate sodium; HC, Healthy control; SD, Standard deviation; SNHG5, Small nucleolar RNA host gene 5; GLP-2, Glucagon-like peptide 2; GSE, Gene set enrichment; ECM, Extracellular matrix; TCA, Tricarboxylic acid cycle; NA, Not available."
5.	Reperfusion Injury 05/01/2005 - "[Protective effects of glucagon-like peptide 2 on intestinal ischemia/reperfusion injury in mice]." 01/01/2006 - "To investigate the effect of glucagon- like peptide 2 on intestinal mucosa immunity after ischemia/reperfusion injury and explore the possible mechanisms. " 01/01/2006 - "[Effect of glucagon-like peptide 2 on the intestinal mucosal immunity and correlative cytokines in mice with gut ischemia/reperfusion injury]." 03/01/2005 - "Uncoupling protein 2 involved in protection of glucagon-like peptide 2 in small intestine with ischemia-reperfusion injury in mice."

Related Drugs and Biologics

1.	teduglutide
2.	Intercellular Signaling Peptides and Proteins (Growth Factors)
3.	Interleukin-6 (Interleukin 6)
4.	Cytokines
5.	Proteins (Proteins, Gene)
6.	Occludin
7.	Claudin-2
8.	Cyclooxygenase 2 (Cyclooxygenase-2)
9.	NF-kappa B (NF-kB)
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Parenteral Nutrition
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Home Parenteral Nutrition
5.	Transplantation